Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cefiderocol - Shionogi

Drug Profile

Cefiderocol - Shionogi

Alternative Names: Cefiderocol-sulfate-tosylate; FETROJA; GSK 2696266; RSC 649266; S-649266

Latest Information Update: 04 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shionogi
  • Class Antibacterials; Cephalosporins
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Registered Urinary tract infections
  • Preregistration Gram-negative infections
  • Phase I Pneumonia

Most Recent Events

  • 22 Nov 2019 Shionogi terminates phase-I trial in Pneumonia (Adjunctive treatment) in USA due to slow enrollment (IV) (NCT03862040)
  • 14 Nov 2019 Registered for Urinary tract infections (Complicated) in USA (IV)
  • 14 Nov 2019 FDA assigns PDUFA action date of 14/11/2019 for Cefiderocol for Gram-negative infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top